Study Breakdown: The Real-World Psilocybin Study From Oregon Is Being Oversimplified

Home | Community | Message Board

You are not signed in.
New Account

Forum Index Search Posts Trusted Vendors Highlights Galleries FAQ User List Chat Store Random Growery

This site includes paid links. Please support our sponsors.

Mushrooms, Mycology and Psychedelics > Psychedelic Medicine, Research & Microdosing

Welcome to the Shroomery Message Board! You are experiencing a small sample of what the site has to offer. Please or register to post messages and view our exclusive members-only content. You'll gain access to additional forums, file attachments, board customizations, encrypted private messages, and much more!

Shop:

Unfolding Nature: Being in the Implicate Order

High THC Strains

Mono Tub Substrate

Jump to first unread post

Pages: 1

ThePsyIntegrCoach
ThePsychedelicIntegrationCoach

Registered: 09/10/26
Posts: 6
Last seen: 34 minutes, 40 seconds

Study Breakdown: The Real-World Psilocybin Study From Oregon Is Being Oversimplified

#29670069 - 09/16/26 07:42 AM (7 days, 13 hours ago)

The first observational study of a U.S. state-regulated psilocybin program was released last month, and it revealed both surprising and unsurprising results.

The study examined the outcomes of Oregon’s regulated psilocybin services, tracking 346 clients enrolled in 24 service centers between November 2024 and March 2026.

One thing that makes this study unique is that it wasn’t restricted to people with treatment-resistant depression or other strict qualifiers for a clinical trial. Rather, adults ages 21 years and older could seek services for any reason. Listed in order of prevalence, those reasons included:

74.3% — curiosity

71.4% — to improve or change themselves

64.5% — to treat mental-health symptoms

51.4% — to process trauma

48.0% — connection with others, Earth, or nature

29.2% — spiritual reasons

19.9% — professional burnout

13.6% — reducing substance use

13.0% — physical-health symptoms

9.8% — coping with death

9.0% — fun/enjoyment/celebration

That makes the following results particularly interesting because the researchers observed changes in mental-health measures across the whole group, not just among people who initially sought treatment for a psychiatric disorder.

First, let’s take a look at some of the key takeaways most people talking about this study will highlight:

92.2% of participants said they benefited from their session.

89.4% said they saw their life and problems from a broader perspective.

58.6% of people ranked their session among the 10 most meaningful experiences of their life.

Depression symptoms dropped from 42.2% of participants at baseline to 16.5%.

Anxiety symptoms dropped from 45.1% to 13.2%.

PTSD symptoms dropped from 48.0% to 16.8%.

Life satisfaction rose from 63.0% to 82.3%.

If you’ve worked with psychedelics yourself, none of that will surprise you. These results are real, and worth taking seriously as more states consider offering psychedelic clinics to the public.

The study reports that, “Many participants experienced decreases in anxiety, depression, and PTSD symptoms within the first month of their psilocybin experience that were sustained at 3 months.” But let’s take a closer look at one of the patterns that arise once you dig in.

Depression symptoms: 42.2% at baseline → 10.6% at 1 month → 16.5% at 3 months.

Do you notice the slight rebound?

The study reported that 90.6% of people attended at least one integration session, with the average number of integration sessions attended per person at one month being 1.9. Strangely, it doesn’t report that number at three months. To me, this lack of data is a missed opportunity to see if perhaps a higher or lower number of integration sessions as time went on correlated with that rebound effect.

That’s just a hypothesis, but let’s look at some other numbers.

At one month, 81.6% reported that their goals were met, while 81% said the experience was “worth the money.”

That’s the majority, right? Hurrah!

But if you flip those numbers around, that means nearly 1 in 5 people did not have their goals met, and did not report the experience being worth the cost. 32.1% even said the cost was a financial strain. That’s a pretty good chance of walking away unsatisfied with a financial burden.

I wonder here, too, if 1.9 reported integration sessions fell shy of helping people walk away satisfied.

Why? Let’s look at some of the reasons these folks may have felt that way.

If you’re unfamiliar with Hallucinogen Persisting Perception Disorder, it can be defined as something like a non-psychotic condition where a person experiences lasting or recurring visual disturbances and perceptual distortions long after using psychedelic drugs. HPPD-type symptoms were reported by 10.0% at one month and 8.7% at three months. While only 1 participant reported that they caused “significant distress,” 1 in 10 people affected seems high.

Non-HPPD “adverse reactions of special interest” were reported by 11.6% at three months:

Headaches lasting more than a day were reported by 2.9%.

Illness lasting more than a day was reported by 3.5%.

Persistent worsening anxiety was reported by 2.3%.

Persistent worsening depression was reported by 4.5%.

Visits to a health professional were reported by 1.3%.

New prescription medications were reported by 1.6%.

New thoughts of dying or suicide were reported by 1.9%.

Imagine being one of the 74.3% of people signing up for one of these sessions out of “curiosity,” or the 9% for “fun,” and three months later you’re having thoughts of suicide. That doesn’t seem like much fun to me.

For the 2.3% of participants who after three months agreed that their experience had been harmful, was an unrecorded number integration sessions somewhere around 1.9 suitable? Would more have changed the long-term outcome?

These are questions, not answers. But let’s take the four cases that involved serious behavioral adverse reactions requiring medical attention. Two of them had no facilitator-reported adverse reaction during the session, yet participants later described emergency-department care, severe anxiety/depression, new medication, insomnia, or suicidal thoughts.

The authors say, “State mandates for collecting safety events are limited to those occurring within 3 days of services, underestimate actual safety events over time, and cannot contextualize risks in light of benefits.” This example makes a case that safety and integration needs should extend beyond just ceremony day, as reporting focused strictly on the day of the session could underestimate adverse reaction rates later. The authors go on to say, “States seeking to implement psychedelic services should assess longitudinal client safety and outcomes in the months following receipt of state-regulated services.”

Again, hypothesis, but perhaps being coached on how to take care of yourself physically before and after a psychedelic session could mitigate some of the headaches or illness. Perhaps being trained on specific depression- or anxiety-reducing techniques could help reduce those symptoms. Perhaps working through various integration exercises could get at the root of what’s amplifying that depression or anxiety in the first place. Perhaps being equipped with frameworks of understanding how to make sense of what they saw could have made the return back to normal life smoother. Or maybe simply having an understanding ear to talk to could make all the difference for someone going through life-altering experiences. At least for some of the 1 in 5 people who walked away unsatisfied.

Now, what about preparation?
Could better preparation have mitigated some of these negative results?

193 of 346 participants had reported using a psychedelic at some point in their lives, meaning that 44.2% of participants had never used a psychedelic before. Nearly all (99.7%) attended at least one preparation session, but is one enough?

Here’s a stat: 88.8% of participants felt safe during the psychedelic experience.

Flipped around? More than 1 in 10 people did not report feeling safe during their experience.

Was this because nearly half of all participants had never experienced this before, walked into a clinic full of strangers after a single “Are you ready for the craziest experience of your life?” pep talk, and then a pat on the back on their way out the door after a single, “Eh? Wasn’t that crazy!?” integration session?

We don’t know. It would have been nice if there was more information on arguably the most important parts of these psychedelic sessions, but there’s no description of what those look like. My concern is that I’ve personally spoken to people who’ve gone through these kinds of clinics and been sent off into the world without the proper support or resources, and were troubled afterwards at a loss of what to do or who to talk to. Additional survey questions here inquiring about why 1 in 5 people were walking away from these expensive experiences unsatisfied might be something for future researchers to consider.

So, what can we conclude from this study?
The biggest contribution is that we now have longitudinal data from a real-world state-regulated psychedelic system, rather than only from highly selected clinical-trial participants. We can see that many people aren’t approaching an experience only as a psychiatric intervention; they are looking for self-change, perspective, trauma processing, connection, or existential meaning also.

The overall results are nuanced: most people reported meaningful benefits—like mental-health symptoms and life satisfaction improvement—while serious adverse events were uncommon, but low frequency is not zero risk.

Because of the uncontrolled, observational nature of the study, we can’t responsibly conclude that psilocybin caused the improvements in this population of roughly 5% of people receiving state-regulated psilocybin services in Oregon during the study period.

However, we can say something like: Most participants improved after receiving regulated psilocybin services under Oregon’s particular regulatory and support model, which, as the authors put it, “may not reflect experiences associated with unsupervised or religious psilocybin use,” and could also be attributed to other possibilities—including preparation, facilitator support, integration, changes in behavior, or some combination of other factors.

Perhaps most important for people in this evolving field is that 90.6% of participants reported receiving integration—which is great. But the question remains, at least in my mind, as to whether an average of 1.9 sessions is enough? The authors also concluded that “ongoing technical support for the emerging facilitator workforce may further reduce the likelihood of harms in vulnerable clients and provide ongoing support for people experiencing postpsychedelic difficulties.”

Source: Korthuis PT, Cook RR, Gregoire D, et al. Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services. JAMA Netw Open. 2026;9(8):e2630608.

--------------------
Grab a free copy of my book 10 Quick Tips For A Psilocybin Trip here:
https://tinyurl.com/y4nd8a9p

Or by subscribing to my newsletter:
https://thepsychedelicintegrationcoach.substack.com/subscribe

And check out ko-fi.com/kylewoodruff for my other relevant books:
- 20 Frameworks For Psychedelic Integration
- A Quick What, Who, Why, Where, How & When of Microdosing Magic Mushrooms
- Psychedelic Prep, Trip, & Integration Workbook

Extras:

Top

Jump to top